Favorable Drug Pricing Language In COVID-19 Government Contracts May Backfire for Industry
Executive Summary
Pharma has won pricing battles during the pandemic, but doesn’t seem to be winning war as senators on both sides of the aisle question how some drug companies were able to skirt controversial intellectual property ownership issues in COVID-19 drug and vaccine agreements with the US government. IP experts say the biggest harm to the government from the contracting language may not be the pricing concerns but the government’s ability to share leanings from the partnerships with other coronavirus development programs.
You may also be interested in...
US-Funded Research On Remdesivir Did Not Produce ‘Patentable’ Discoveries
US government agencies were given the right to pursue patents on remdesivir in research contracts negotiated with Gilead but did not do so, the Government Accountability Office reports.
Congress Eyes Vaccine Pricing With Spotlight On Pfizer As COVID Boosters Look More Likely
Senate hearing offers early signals that US lawmakers will be closely watching how COVID-19 vaccine pricing evolves. Biden team pledges to try to make contracting more transparent.
Pharma Industry Reputation: What Is At Stake With COVID-19?
The massive need for a COVID-19 vaccine and treatments has heightened the biopharmaceutical industry’s visibility among consumers and the world’s largest biopharma companies are getting a boost in positive perception this year, according to a new FutureBrand survey. If sustained, this could have dividends in areas such as attracting industry talent and clinical trial participants. But much remains to be seen as biopharma navigates the final stretch of clinical development, regulatory review, distribution and patient access.